Tempus HRD-RNA is an AI-driven, 1,660-gene logistic regression model designed to identify patients likely to respond to ...
Per Porsche Consulting’s analysis, artificial intelligence (“AI”), especially generative AI, is rapidly transforming MedTech ...
CHICAGO--(BUSINESS WIRE)-- Northwestern Medicine and Tempus AI, Inc. (TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provide ...
Tempus AI TEM rose on Wednesday after the company unveiled its new HRD-RNA algorithm, an AI-driven tool designed to improve detection of homologous recombination deficiency (HRD) in tumors. The ...
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm ...
Hosted on MSN
Tempus AI Expands “Tempus Next” Platform to Improve Breast Cancer Care with AI-Driven Insights.
Tempus AI Inc. (NASDAQ:TEM) is one of the best young stocks to buy and hold for 5 years. On July 8, Tempus AI announced the expansion of its care pathway intelligence platform, called Tempus Next, to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results